Background and Purpose—Although rivaroxaban 15 mg (R15) was only given to patients
with creatinine clearance (CrCl)≤ 50 mL/min in the pivotal clinical trial, this dose has been …

Objective To investigate the association between body mass index (BMI) and oral
anticoagulant (OAC) prescription in atrial fibrillation (AF). Methods Patients with newly …

In Japanese surveillance in an early phase after the approval of rivaroxaban, inappropriate
underdose was frequently utilized. The aim of this study was to describe the prevalence and …

Background: The J-ROCKET AF study found that rivaroxaban was non-inferior to warfarin
with respect to the principal safety outcome in patients with atrial fibrillation (AF). The aim of …

Abstract Background The XANTUS study (NCT01606995) demonstrated low rates of stroke
and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical …

Objective To compare the clinical benefits of rivaroxaban and warfarin in patients with non-
valvular atrial fibrillation (NVAF) with high bleeding risk. Methods A retrospective study was …

Diabetes mellitus (DM) is a common co-morbidity in those with nonvalvular atrial fibrillation
(NVAF). Most patients with DM and NVAF have a CHA 2 DS 2-VASc score of≥ 1 and should …

Background Direct‐acting oral anticoagulants are now the preferred method of
anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these …

Background: Reduced-dose rivaroxaban (10 mg) was used in the J-ROCKET AF trial,
demonstrating safety in the Asian population. It remains unclear whether treatment with …

Abstract Background The ROCKET AF study evaluated once-daily rivaroxaban versus dose-
adjusted warfarin for the prevention of stroke and systemic embolism in patients with atrial …